Healthcare
Live Price
Offline$6.16
+3.53% today
1Y Change
-18.10%
Window
Jun 23, 2025 → Jun 8, 2026
Coverage: 241 bars · Jun 23, 2025 → Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Wave Life Sciences Ltd. (WVE) is a Healthcare stock with a market cap of $1.44B and listed on NASDAQ. The stock last traded around $6.16 and down 18.1% across the available one-year price window (Jun 23, 2025 → Jun 8, 2026). Baseline metrics include revenue growth of -60.5%, EPS growth of -72.9%, a dividend yield of 0.0%. What stands out right now is revenue -60.5%, EPS -72.9%, free cash flow -23.4% with operating margin -274.2% and ROIC -36.3%. Valuation already assumes a fairly strong business story at price/sales 20.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines WVE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WVE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WVE Max Drawdown
-73.30%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WVE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$41.0M
+1022.6% YoY
FY Net Income
-$122.2M
+24.5% YoY
Free Cash Flow
-$89.6M
+30.7% YoY
Revenue Growth
-60.5%
EPS Growth
-72.9%
Gross Margin
93.8%
Net Margin
-255.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 43M | 108M | 113M | 4M | 41M |
| Gross Profit | 34M | 108M | 113M | 4M | 41M |
| Operating Income | -215M | -110M | -68M | -163M | -127M |
| EBITDA | -196M | -102M | -59M | -153M | -117M |
| Net Income | -204M | -97M | -58M | -162M | -122M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 602M | 302M | 200M | 88M | 151M |
| Total Assets | 638M | 352M | 275M | 146M | 207M |
| Total Liabilities | 112M | 143M | 235M | 191M | 175M |
| Shareholder Equity | 526M | 210M | 40M | -45M | 32M |
| Total Debt | 18M | 25M | 32M | 38M | 30M |
| Net Debt | -584M | -277M | -168M | -51M | -121M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
89M
+30.4% YoY
Capital Expenditures
560K
+58.9% YoY
Free Cash Flow
90M
+30.7% YoY
Key ratios
Gross Margin
93.8%
Operating Margin
-274.2%
Net Margin
-255.7%
ROE
-56.4%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.